This stock is no longer traded. It was delisted on September 25, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
Theravance Biopharma Inc. is a biopharmaceutical company focused on developing and commercializing medicines for respiratory disease and selected specialized conditions. Its commercial portfolio is centered on YUPELRI, an inhaled therapy used in chronic obstructive pulmonary disease (COPD), supported by a broader respiratory franchise that addresses patient needs in outpatient and clinical care settings. The company also pursues medicines for rare and complex disorders, including ampreloxetine, an investigational therapy studied for symptomatic neurogenic orthostatic hypotension associated with multiple system atrophy. Theravance Biopharma Inc. works across research, clinical development, and product commercialization, giving it a role in advancing treatments from late-stage development to market access. Based in South San Francisco, California, the company operates as a focused healthcare business serving physicians, patients, and healthcare systems with therapies designed for chronic management and specialty care.
Website901 Gateway Boulevard
South San Francisco, CA, 94080
United States
The latest articles about TBPH.
Zymeworks completes its Theravance Biopharma acquisition, boosts 2026 revenue guidance, and gains recurring revenue from YUPELRI sales.
Summary of Jun 29's posts. Generated by AI.
Summary of Jul 18's posts. Generated by AI.
Zymeworks (ZYME) said Monday it has completed its acquisition of Theravance Biopharma, adding Yupelr
Summary of Sep 16's posts. Generated by AI.
Summary of Jun 29's posts. Generated by AI.
Investors talking about TBPH also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.